CNBX Pharmaceuticals Inc. (CNBX)

Market Cap	112.71K
Revenue (ttm)	n/a
Net Income (ttm)	-224.45K
Shares Out	187.84M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,400,003
Average Volume	19,248,524
Open	0.0006
Previous Close	0.0006
Day's Range	0.0005 - 0.0006
52-Week Range	0.0005 - 0.0199
Beta	0.19
RSI	37.20
Earnings Date	Jul 11, 2025

About CNBX Pharmaceuticals

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast canc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: CNBX

Financial Performance

In 2024, CNBX Pharmaceuticals's revenue was $130,074, a decrease of -68.29% compared to the previous year's $410,165. Losses were -$695,198, -81.26% less than in 2023.